New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
08:06 EDTEPZMEpizyme receives $4M milestone and license payment
Epizyme announced the achievement of the lead candidate milestone for the third of the three histone methyltransferase targets in the company's collaboration with GSK and is receiving $4M in milestone and license payments. Previously, Epizyme announced the achievement of a $4M development candidate milestone for the first GSK collaboration target in January and a $2M lead candidate selection milestone for the second GSK collaboration target in February.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:38 EDTEPZMEpizyme update for EPZ-6438 encouraging, says Mizuho
Subscribe for More Information
06:33 EDTEPZMEpizyme to host conference call
Conference call to discuss results from the Phase 1 dose escalation study of the investigational EZH2 inhibitor EPZ-6438 will be held on November 20 at 8 am. Webcast Link
November 19, 2014
18:06 EDTEPZMEpizyme reports results from Phase 1 dose study of EZH2 inhibitor EPZ-6438
Subscribe for More Information
November 18, 2014
07:20 EDTEPZMEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use